Texas Permanent School Fund Corp Lowers Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Texas Permanent School Fund Corp reduced its position in Omnicell, Inc. (NASDAQ:OMCL) by 14.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,032 shares of the company’s stock after selling 5,598 shares during the quarter. Texas Permanent School Fund Corp owned about 0.07% of Omnicell worth $921,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC grew its stake in Omnicell by 197.9% during the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock worth $3,642,000 after buying an additional 82,774 shares during the period. Assenagon Asset Management S.A. grew its stake in Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after buying an additional 228,093 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Omnicell in the first quarter worth $684,000. Finally, Cadian Capital Management LP purchased a new position in shares of Omnicell in the 4th quarter valued at $2,446,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Ratings Changes

OMCL has been the subject of a number of research reports. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday. Wells Fargo & Company increased their target price on Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. raised their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Bank of America boosted their price target on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Benchmark reaffirmed a “buy” rating and set a $38.00 price target on shares of Omnicell in a report on Monday, July 15th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $37.83.

Omnicell Trading Up 2.8 %

Shares of NASDAQ OMCL opened at $44.62 on Friday. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $53.37. The business has a fifty day simple moving average of $39.21 and a 200-day simple moving average of $32.24. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -97.00, a P/E/G ratio of 47.22 and a beta of 0.83. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. Sell-side analysts predict that Omnicell, Inc. will post 0.64 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.